TELA Bio Announces Board Refreshment and Preliminary Q1 2026 Revenues
TELA Bio, Inc. has announced a strategic board refreshment plan aimed at supporting its growth and operational excellence, with four new directors set to join after the 2026 Annual Meeting. The changes are motivated by the need for deep expertise in medtech commercialization and financial strategy. The company also reported preliminary revenues for Q1 2026 at approximately $19.0 million, exceeding prior guidance of $18.5 million.
MALVERN, Pa., April 30, 2026 (GLOBE NEWSWIRE) — TELA Bio, Inc. (“TELA Bio”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced a comprehensive board refreshment plan designed to support the Company’s next phase of commercial growth and operational excellence.